-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 26, 2021 //---According to a recent study, scientists from the University of Arizona School of Health Sciences examined the role of cholesterol in Alzheimer’s disease and type 2 diabetes to identify the potential for regulating the brain Cholesterol level is a small molecule, and may become a potential new therapeutic target for Alzheimer's disease.
Alzheimer's disease affects more than 5.
5 million people in the United States, and there is currently no effective treatment for this disease.
In the past decade, more and more evidence has established a link between type 2 diabetes and Alzheimer's disease.
5 million people in the United States, and there is currently no effective treatment for this disease.
In the past decade, more and more evidence has established a link between type 2 diabetes and Alzheimer's disease.
(Image source: www.
pixabay.
com)
pixabay.
com)
When insulin is less effective in removing glucose from the blood, it can lead to type II diabetes, which can lead to high blood sugar and possibly abnormal cholesterol levels.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
Dr.
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
When cholesterol rises due to insulin resistance or other factors, the human body will begin to reverse cholesterol transport.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
Apolipoprotein E (APOE) is one of the proteins involved in the reverse transport of cholesterol.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Alzheimer's disease affects more than 5.
5 million people in the United States, and there is currently no effective treatment for this disease.
In the past decade, more and more evidence has established a link between type 2 diabetes and Alzheimer's disease.
5 million people in the United States, and there is currently no effective treatment for this disease.
In the past decade, more and more evidence has established a link between type 2 diabetes and Alzheimer's disease.
(Image source: www.
pixabay.
com)
pixabay.
com)
When insulin is less effective in removing glucose from the blood, it can lead to type II diabetes, which can lead to high blood sugar and possibly abnormal cholesterol levels.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
Dr.
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
When cholesterol rises due to insulin resistance or other factors, the human body will begin to reverse cholesterol transport.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
Apolipoprotein E (APOE) is one of the proteins involved in the reverse transport of cholesterol.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
(Image source: www.
pixabay.
com)
pixabay.
com)
When insulin is less effective in removing glucose from the blood, it can lead to type II diabetes, which can lead to high blood sugar and possibly abnormal cholesterol levels.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
Dr.
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
When cholesterol rises due to insulin resistance or other factors, the human body will begin to reverse cholesterol transport.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
Apolipoprotein E (APOE) is one of the proteins involved in the reverse transport of cholesterol.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
When insulin is less effective in removing glucose from the blood, it can lead to type II diabetes, which can lead to high blood sugar and possibly abnormal cholesterol levels.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
A similar situation also occurs in Alzheimer's disease, but this effect does not affect the entire body, but is limited to the brain.
Dr.
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
When cholesterol rises due to insulin resistance or other factors, the human body will begin to reverse cholesterol transport.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
Apolipoprotein E (APOE) is one of the proteins involved in the reverse transport of cholesterol.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Dr.
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
Gregory Thatcher, Professor of Pharmacology and Toxicology at the Arizona School of Pharmacy, said: “Alzheimer’s disease and diabetes have many common features.
Our goal is to develop a method to identify compounds that can counteract many of the causes that cause Alzheimer’s.
Harmful changes in Hymer’s disease and type 2 diabetes.
"
When cholesterol rises due to insulin resistance or other factors, the human body will begin to reverse cholesterol transport.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
Apolipoprotein E (APOE) is one of the proteins involved in the reverse transport of cholesterol.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
When cholesterol rises due to insulin resistance or other factors, the human body will begin to reverse cholesterol transport.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
In this process, specific molecules will carry excess cholesterol to the liver and be excreted from the body.
Apolipoprotein E (APOE) is one of the proteins involved in the reverse transport of cholesterol.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Apolipoprotein E (APOE) is one of the proteins involved in the reverse transport of cholesterol.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
APOE is also the strongest risk factor gene for Alzheimer's disease and related dementia, and an independent risk factor for type II diabetes and cardiovascular disease.
Similarly, decreased activity of another cholesterol transporter, ATP-binding cassette transporter A1 (ABCA1), is associated with increased risk of cardiovascular disease, type II diabetes, and Alzheimer's disease.
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
"Although most people are aware of the so-called'good cholesterol' and'bad cholesterol' concepts related to the risk of heart attack and stroke, these concepts also apply to the brain.
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
Moving cholesterol to the desired location in the body is important for many physiological processes.
All have a positive effect and can help eliminate misfolded proteins that accumulate in the brain.
"
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
The authors estimate that increasing the activity of ABCA1 can positively affect insulin signaling and reduce inflammation in the brain, making it a potential treatment for type II diabetes and Alzheimer's disease.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In this study, Dr.
Thatcher and the research team developed a small molecule that can identify ABCA1 functions in the body while avoiding adverse effects on the liver.
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
In a paper recently published in the journal EBioMedicine, Dr.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Thatcher’s research team studied a specific small molecule CL2-57.
The study showed that this molecule can stimulate the activity of ABCA1 and simultaneously affect the liver and plasma triglycerides.
Ester has a positive effect.
In addition, the use of the compound showed improved glucose tolerance and insulin sensitivity, slowed weight gain, and other beneficial effects.
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Their future research will seek to improve the properties of small molecules to increase levels in the brain.
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Their long-term goal is to understand which patients with cognitive and neuropsychiatric symptoms of Alzheimer's and dementia will benefit from treatment.
(Bioon.
com)
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease.
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Source of information: com/news/2021-03-cholesterol-key-therapies-alzheimer-disease. html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
html">Cholesterol may be key to new therapies for Alzheimer's disease, diabetes
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Original source: Manel Ben Aissa, Cutler T.
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
：Manel Ben Aissa, Cutler T. Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149
Lewandowski, Kiira M.
Ratia et al, acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes, ACS Pharmacology & Translational Science (2021).
DOI: 10.
1021/acsptsci.
0c00149acs.
org/doi/10.
1021/acsptsci.
0c00149">Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes,ACS Pharmacology & Translational Science
